Gilead submits NDA to FDA for Viread

FOSTER CITY, Calif. Gilead Sciences has submitted a new drug application to the Food and Drug Administration for its drug Viread, for the treatment of chronic hepatitis B in adults.

The drug is already approved in the U.S. for the treatment of HIV as part of a combination antiretroviral therapy.  The company is asking for the new application after successful data from two Phase III trials that were compared with the company’s hepatitis medication Hepsera.